Search results

Selected filters:

North America

Article type

Topic

Sector

Jurisdictions

3,281 results found for your search

Sort options
15 February 2019

AbbVie’s Humira strategy to be scrutinised in first evergreening unclean hands challenge

In a Delaware case Boehringer Ingelheim accuses the Illinois company of improper conduct in deliberately constructing a patent thicket to protect against generic versions of its blockbuster drug.

14 February 2019

As 101 debate continues, Iancu offers clear message to Federal Circuit

With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent

14 February 2019

The five key takeaways from the USPTO’s report on women and patents

Although female patentees are becoming more common – particularly in areas such as pharma and biotech – the rate of growth is slowing, suggesting that a lot more work needs to be done before equality between the sexes is achieved

14 February 2019

World’s most valuable startup buys patents again

The company behind Tik Tok bought out much of a struggling smartphone maker’s patent portfolio in January. USPTO assignments from last week show what assets Beijing-based ByteDance came away with

13 February 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco 

13 February 2019

Supreme Court declines to narrow on-sale bar

In Helsinn Healthcare SA v Teva Pharmaceuticals USA, Inc, the Supreme Court has unanimously declined to narrow the on-sale bar to public sales only in light of new language in the America Invents Act.

12 February 2019

AT&T’s portfolio is a treasure trove for buyers

The telecoms giant is building its presence in the secondary market with a host of companies now seeking out its high-quality patents  

12 February 2019

New investment platform aims to break down barriers to capital for innovators

Former IV unit teams up with alternative asset business to give large and small innovators way of attracting finance on Blockchain-based initiative

11 February 2019

RPX strikes deal to acquire remaining patent portfolio of Creative subsidiary

The settlement deal ends litigation by the Singapore company’s ZiiLabs unit against Nvidia, and will net shareholders around $17.5 million

08 February 2019

Japan's Wacom bulks up patent portfolio

The high-end maker of tablets and styluses for artists and designers makes its latest patent acquisition amidst new US litigation and a push to reach more consumers with competitively priced offerings

08 February 2019

The US’s first all biosimilar patent suit shows new pharma IP landscape is emerging

Coherus launched Delaware action against Amgen in what is likely to become an increasingly familiar life sciences litigation scenario.

08 February 2019

US patent system jumps to second in the world, though the biopharma sector may not agree

PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies

07 February 2019

An entire “industry revolt” hinges on judge’s decision in FTC v Qualcomm

If the Commission and Apple are successful in rewriting the rules for chipmaker's licensing arm beware of unintended consequences that reduce choice and harm consumers, expert analyst states

07 February 2019

Pantech deals more patents, this time to Oppo

Sell-off continues as new ownership seeks to get out from under nearly $100 million in debt with just a few hundred granted US patents remaining in its arsenal

06 February 2019

165-year-old brand alleges trademark infringement against best-selling video game

The Red Dead 2 lawsuit spotlights how trademark infringement claims require trademark use. It is never sufficient to simply claim "you can't do that, it's trademarked”. Whether ‘use’ constitutes trademark use, and whether it is permissible, is a nuanced analysis.